By
Trending Posts
GSK Expands AI Capabilities with $70 Million Tempus…
London, UK – October 18, 2022 GSK has entered into a $70 million agreement with Tempus, a leader…
Eli Lilly and Genesis AI Announce $670M AI-Driven…
BURLINGAME, California – May 3, 2022 Harnessing AI to Unlock Breakthrough Therapies Eli Lilly and Company and Genesis…
Genesis AI and Genentech (Roche) Form Multi-Target AI…
BURLINGAME, California – Oct 19, 2020 Genesis Therapeutics, a pioneer in AI-driven drug discovery, has announced a multi-target…
Trending Posts
Latest Stories
Can MIT and Recursion’s New AI Model Boltz-2 Slash Drug Discovery Time by 1000x and Outperform AlphaFold3?
Key Takeaways• Boltz-2 delivers AI-driven binding affinity predictions 1000x faster than traditional free energy methods—dramatically…
Is Optic and Mechanica’s AI Venture Model the Future of Biotech Creation? Strategic Expansion Unifies Drug Discovery and Business Insight at Scale
Key Highlights Strategic Collaboration to Power AI-Led Biotech GrowthOptic, Inc., a pioneer in AI platforms…
Is the OBI Pharma–TegMine Therapeutics ADC Deal the Next Leap in Precision Oncology Using Glycan-Based Technologies?
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between…
Can AI Reveal the Hidden Biology of Cancer? Aitia and Gustave Roussy Join Forces to Decode Disease Causality for Next-Gen Therapies
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment,…
Gallery
